Forma Therapeutics Holdings

General Information


We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our drug discovery expertise has generated a pipeline of small molecule product candidates focused on indications with significant unmet patient need. Our pipeline consists of seven product candidates, two of which we are pursuing as core product candidates for development, FT-4202 for the treatment of sickle cell disease, or SCD, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

Employees: 80
Founded: 2007
Contact Information
Address 500 Arsenal Street, Suite 100, Watertown, MA 02472, US
Phone Number (617) 679-1970
Web Address
View Prospectus: Forma Therapeutics Holdings
Financial Information
Market Cap $625.2mil
Revenues $28.5 mil (last 12 months)
Net Income $-51.2 mil (last 12 months)
IPO Profile
Symbol FMTX
Exchange NASDAQ
Shares (millions): 13.9
Price range $20.00 - $20.00
Est. $ Volume $277.6 mil
Manager / Joint Managers Jefferies/ SVB Leerink/ Credit Suisse
CO-Managers -
Expected To Trade: 6/19/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change